

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 December 2021 (16.12.2021)



(10) International Publication Number
WO 2021/252835 A1

(51) International Patent Classification:
C07K 16/10 (2006.01)

(21) International Application Number:
PCT/US2021/036923

(22) International Filing Date:
11 June 2021 (11.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/038,433 12 June 2020 (12.06.2020) US

(71) Applicants: **AMPLYX PHARMACEUTICALS, INC.**
[US/US]; 12730 High Bluff Drive, Suite 160, San Diego,
California 92130 (US). **NOVARTIS AG** [CH/CH]; Licht-
strasse 35, 4056 Basel (CH).

(72) Inventors: **ABEND, Johanna, R.**; c/o Novartis Insti-
tutes for BioMedical Research, Inc., 5300 Chiron Way,
Emeryville, California 94608 (US). **KNAPP, Mark**; c/o
Novartis Institutes for BioMedical Research, Inc., 5300
Chiron Way, Emeryville, California 94608 (US). **KO-
VACS, Steven, J.**; c/o Novartis Pharmaceuticals Corpora-
tion, One Health Plaza, East Hanover, New Jersey 07936

(US). **PATICK, Amy, K.**; 1418 Union St., Alameda, Cal-
ifornia 94501 (US). **TRAGGIAI, Elisabetta**; c/o Novartis
Pharma AG, Postfach, 4002 Basel (CH).

(74) Agent: **CHRISTIANSEN, William T.** et al.; Cooley LLP,
1299 Pennsylvania Avenue, NW, Suite 700, Washington,
District of Columbia 20004-2400 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: DOSING OF POLYOMAVIRUS NEUTRALIZING ANTIBODIES




FIG. 1

(57) Abstract: Provided are dosing regimens of polyomavirus neutralizing antibodies and related methods and pharmaceutical compositions for treating polyomavirus infections.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*